Cancer Anorexia - Pipeline Review, H2 2012


#156217

22pages

Global Markets Direct

$ 2000

In Stock


Global Markets Directs, 'Cancer Anorexia Pipeline Review, H2 2012', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Cancer Anorexia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cancer Anorexia. 

Cancer Anorexia Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Cancer Anorexia.
  • A review of the Cancer Anorexia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Cancer Anorexia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Cancer Anorexia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Cancer Anorexia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table Of Contents

Table of Contents 2
List of Tables 3
List of Figures 3

Introduction 4
Global Markets Direct Report Coverage 4
Cancer Anorexia Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Cancer Anorexia 6
Cancer Anorexia Therapeutics under Development by Companies 8
Cancer Anorexia Therapeutics under Investigation by Universities/Institutes 9
Late Stage Products 10
Comparative Analysis 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Cancer Anorexia Therapeutics - Products under Development by Companies 13
Cancer Anorexia Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Cancer Anorexia Therapeutics Development 15
Helsinn Healthcare S.A. 15
Cancer Anorexia - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Combination Products 17
Cancer Anorexia Therapeutics - Dormant Products 18
Cancer Anorexia - Product Development Milestones 19
Featured News & Press Releases 19
Dec 07, 2011: Helsinn Initiates Extension Study In Late-Stage Anamorelin Clinical Program For Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia 19
Aug 24, 2011: Helsinn Therapeutics Initiates Phase III Clinical Program To Evaluate Anamorelin In Non-Small Cell Lung Cancer-Associated Anorexia/Cachexia 19
Nov 03, 2010: Ohr Pharmaceutical Inc. Announces $244,000 Grant Award 20

Appendix 21
Methodology 21
Coverage 21
Secondary Research 21
Primary Research 21
Expert Panel Validation 21
Contact Us 22
Disclaimer 22

Number of Products Under Development for Cancer Anorexia, H2 2012 6
Products under Development for Cancer Anorexia - Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Mid Clinical Stage Development, H2 2012 11
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 12
Products under Development by Companies, H2 2012 13
Products under Investigation by Universities/Institutes, H2 2012 14
Helsinn Healthcare S.A., H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17
Cancer Anorexia Therapeutics - Dormant Products 18
Number of Products under Development for Cancer Anorexia, H2 2012 6
Products under Development for Cancer Anorexia - Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Late Stage Products, H2 2012 10
Mid Clinical Stage Products, H2 2012 11
Pre-Clinical Stage Products, H2 2012 12
Assessment by Monotherapy Products, H2 2012 16
Assessment by Combination Products, H2 2012 17